Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials

A Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Efficacy of Ketamine for the Treatment of Concurrent Opioid Use Disorder and Major Depressive Disorder

To see complete record on, please visit this link

Id: NCT04177706

Organisation Name: Medical University of South Carolina

Overal Status: Recruiting

Start Date: December 17, 2020

Last Update: November 25, 2022

Lead Sponsor: Medical University of South Carolina

Brief Summary: The purpose of the study is to examine whether an investigational medication called ketamine is able to improve treatment outcomes for concurrent opioid addiction and depression when used in conjunction with buprenorphine treatment. Study medications will be delivered twice per week for four weeks. If you are eligible and you decide to enroll in the study, your participation will last approximately 8 weeks, or 2 months.

  • Depression
  • Opioid-use Disorder
  • Opioid Abuse

Total execution time in seconds: 0.24056601524353